Amgen Inc. discovers, develops, manufactures, and delivers human therapeutics worldwide. It focuses on inflammation, oncology/hematology, bone health, cardiovascular disease, nephrology, and neuroscience areas. The company's products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Neulasta that reduces the chance of infection due a low white blood cell count in patients cancer; Prolia to treat postmenopausal women with osteoporosis; Xgeva for skeletal-related events prevention; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease; Aranesp to treat a lower-than-normal number of red blood cells and anemia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; and Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization. It also markets Nplate, Vectibix, MVASI, Parsabiv, EPOGEN, KANJINTI, BLINCYTO, Aimovig, EVENITY, AMGEVITATM, Sensipar/Mimpara, NEUPOGEN, IMLYGIC, Corlanor, and AVSOLA. Amgen Inc. serves healthcare providers, including physicians or their clinics, dialysis centers, hospitals, and pharmacies. It distributes its products through pharmaceutical wholesale distributors, as well as direct-to-consumer channels. It has collaboration agreements with Novartis Pharma AG; UCB; Bayer HealthCare LLC; BeiGene, Ltd.; Eli Lilly and Company; Datos Health; and Verastem, Inc. to evaluate VS-6766 in combination with lumakrastm (Sotorasib) in patients with KRAS G12C-mutant non-small cell lung cancer. It has an agreement with Kyowa Kirin Co., Ltd. to jointly develop and commercialize KHK4083, a Phase 3-ready anti-OX40 fully human monoclonal antibody for the treatment of atopic dermatitis and other autoimmune diseases; and research and development collaboration with Neumora Therapeutics, Inc. and Plexium, Inc. Amgen Inc. was incorporated in 1980 and is headquartered in Thousand Oaks, California.

Amgen Inc.

Revenue

EBIT

EBITDA

CapEx

Net Interest Income

Assets

Adjusted EBITDA

Gross Profit

Adjusted Net Income

Net Revenue

Net Income

Average Assets

Adjusted EBIT

Adjusted Revenue

Adjusted EBT

Adjusted Funds From Operations

McKesson Corporation Revenue

McKesson Corporation Revenue % Chg.

Cencora, Inc. (formerly Amerisource Bergen Corporation) Revenue

Cencora, Inc. (formerly Amerisource Bergen Corporation) Revenue % Chg.

Cardinal Health, Inc. Revenue

Cardinal Health, Inc. Revenue % Chg.

Key Performance Indicators

U.S. Revenue

U.S. Revenue % Chg.

U.S. Revenue Common Size

Rest of World (ROW) Revenue

Rest of World (ROW) Revenue % Chg.

Rest of World (ROW) Revenue Common Size

Total Revenue by Geography

Total Revenue by Geography Common Size

Total Revenue by Geography % Chg.

Revenue by Geography

Prolia Revenue

Prolia Revenue % Chg.

Prolia Revenue Common Size

ENBREL Revenue

ENBREL Revenue % Chg.

ENBREL Revenue Common Size

XGEVA Revenue

XGEVA Revenue % Chg.

XGEVA Revenue Common Size

Repatha Revenue

Repatha Revenue % Chg.

Repatha Revenue Common Size

Otezla Revenue

Otezla Revenue % Chg.

Otezla Revenue Common Size

TEPEZZA Revenue

TEPEZZA Revenue % Chg.

TEPEZZA Revenue Common Size

EVENITY Revenue

EVENITY Revenue % Chg.

EVENITY Revenue Common Size

KYPROLIS Revenue

KYPROLIS Revenue % Chg.

KYPROLIS Revenue Common Size

Nplate Revenue

Nplate Revenue % Chg.

Nplate Revenue Common Size

Aranesp Revenue

Aranesp Revenue % Chg.

Aranesp Revenue Common Size

BLINCYTO Revenue

BLINCYTO Revenue % Chg.

BLINCYTO Revenue Common Size

KRYSTEXXA Revenue

KRYSTEXXA Revenue % Chg.

KRYSTEXXA Revenue Common Size

Vectibix Revenue

Vectibix Revenue % Chg.

Vectibix Revenue Common Size

TEZSPIRE Revenue

TEZSPIRE Revenue % Chg.

TEZSPIRE Revenue Common Size

Other Products Revenue

Other Products Revenue % Chg.

Other Products Revenue Common Size

Product Revenue

Product Revenue % Chg.

Product Revenue Common Size

Other Revenue

Other Revenue % Chg.

Other Revenue Common Size

Total Revenue

Total Revenue Common Size

Total Revenue % Chg.

Revenue	LTM	Dec '24	Dec '23
Prolia Revenue	4,525	4,374	4,048
ENBREL Revenue	2,709	3,316	3,697
XGEVA Revenue	2,198	2,225	2,112
Repatha Revenue	2,752	2,222	1,635
Otezla Revenue	2,264	2,126	2,188
TEPEZZA Revenue	1,906	1,851	448
EVENITY Revenue	1,932	1,563	1,160
KYPROLIS Revenue	1,433	1,503	1,403
Nplate Revenue	1,476	1,456	1,477
Aranesp Revenue	1,364	1,342	1,362
BLINCYTO Revenue	1,527	1,216	861
KRYSTEXXA Revenue	1,251	1,185	272
Vectibix Revenue	1,102	1,045	984
TEZSPIRE Revenue	1,300	972	567
Other Products Revenue	6,758	5,630	4,696
Product Revenue	34,497	32,026	26,910
Other Revenue	1,474	1,398	1,280
Total Revenue	35,971	33,424	28,190

Revenue by Geography	LTM	Dec '24	Dec '23
U.S. Revenue	—	23,863	19,806
Rest of World (ROW) Revenue	—	9,561	8,384
Total Revenue by Geography	35,971	33,424	28,190

Key Performance Indicators	LTM	Dec '24	Dec '23
McKesson Corporation Revenue	—	22,173	19,035
Cencora, Inc. (formerly Amerisource Bergen Corporation) Revenue	—	18,387	16,625
Cardinal Health, Inc. Revenue	—	11,278	9,775